Tsumagari Koji, Chijiiwa Kazuo, Nagai Hisaki, Makita Masujiro, Kasumi Fujio, Akiyama Futoshi, Sakamoto Goi, Miki Yoshio
Department of Surgery I , Miyazaki Medical College, 5200, Kihara, Kiyotake-cho, 889-1692, Miyazaki, Japan.
Breast Cancer. 2005;12(3):166-77. doi: 10.2325/jbcs.12.166.
In Japan, postoperative relapse occurs within five years in 9.2 to 16% of patients whose breast cancers have not metastasized to lymph nodes at the time of initial surgery(node-negative, n0). Attempts to find molecular markers able to classify n0 breast cancers in terms of postoperative prognosis have not been successful.
To identify molecular indicators of prognosis for this type of cancer, we used a cDNA microarray consisting of 25,344 human genes to investigate expression profiles of 12 primary breast cancers from patients whose tumors recurred within five years after surgery(5Y-R) and 12 from patients who survived disease-free for more than five years (5Y-F).
Sets of genes characterizing each group in terms of expression patterns in the tumors were selected by Mann-Whitney and random-permutation tests: these panels included 21 genes expressed highly in 5Y-R tumors than in 5Y-F tumors, and 37 with higher expression in the 5Y-F group than in the 5Y-R group.
We established a scoring system to prediction of postoperative prognosis which was 100% accurate as to the actual clinical outcomes of the 24 cases and therefore might be useful for predicting prognosis of n0 breast cancers in a clinical setting. The prognostic score system clearly separated the two groups without any overlap, and accurately predicted prognosis in 6 additional cases. Moreover, the extensive list of tumor-related genes identified in these experiments provides valuable information about progression of breast cancer and suggests potential target molecules for therapy of n0 breast cancers.
在日本,9.2%至16%的原发性乳腺癌患者在初次手术时淋巴结未发生转移(淋巴结阴性,n0),术后五年内会出现复发。试图寻找能够根据术后预后对n0期乳腺癌进行分类的分子标志物尚未成功。
为了确定这类癌症的预后分子指标,我们使用了一个包含25344个人类基因的cDNA微阵列,来研究12例术后五年内肿瘤复发(5Y-R)患者的原发性乳腺癌和12例无病生存超过五年(5Y-F)患者的原发性乳腺癌的表达谱。
通过曼-惠特尼检验和随机排列检验,根据肿瘤中的表达模式选择了表征每组的基因集:这些基因面板包括21个在5Y-R肿瘤中表达高于5Y-F肿瘤的基因,以及37个在5Y-F组中表达高于5Y-R组的基因。
我们建立了一个预测术后预后的评分系统,该系统对24例患者的实际临床结果预测准确率为100%,因此可能有助于在临床环境中预测n0期乳腺癌的预后。预后评分系统清楚地将两组分开,没有任何重叠,并准确预测了另外6例患者的预后。此外,在这些实验中鉴定出的大量肿瘤相关基因清单提供了有关乳腺癌进展的有价值信息,并暗示了n0期乳腺癌治疗的潜在靶分子。